Article Figures & Data
Figures
- Figure 1 Pedigree, MRI, and muscle histology
(A) Pedigree of a family of Irish descent with evidence of distal neuromuscular disease in I-1, III-1, III-3, and III-5. *DNA was available for Sanger sequencing, **DNA was available for whole-exome and Sanger sequencing. (B) T1 MRI of III-1 demonstrating severe fatty replacement of the muscles of the lower leg with relative sparing of tibialis anterior (green arrows). (C) Less marked fatty replacement and (D) active high short tau inversion recovery signal abnormality of the muscles of the lower thigh, principally affecting biceps femoris and semimembranosus (red arrowheads) but also the vasti, with relative sparing of sartorius and semitendinosus, and complete sparing of the adductors, rectus femoris, and gracilis (green arrows). (E) Minor T1 changes in the upper thigh. Muscle histology of gastrocnemius (III-1) (F–I) and of tibialis anterior (III-5) (J–P). (F) Hematoxylin & eosin (HE) staining demonstrating a wide range of fiber diameters and groups of small fibers, internal nucleation (G), and an increase in endomysial and perimysial fibrous connective tissue. (H) Scattered fibers contain vacuoles without a basophilic rim. Few fibers show acute necrosis or phagocytosis, but there is a small mononuclear cell inflammatory focus around a blood vessel (I). (J) HE staining demonstrating variation in fiber size with round atrophic fibers (K) and a slightly increased frequency of muscle fibers with internal nuclei (L). (M) Oxidative staining with NADH shows mildly moth-eaten fibers and mild subsarcolemmal accentuation in ring-shaped fibers. (N and O) Esterase histochemistry within the inset demonstrates angulated and rounded atrophic fibers with intense esterase staining and internal nuclei. (P) Adenosine triphosphatase (pH 4.3) staining demonstrating fiber-type grouping and some angulated fibers. Gastrocnemius is recognized to be more prone to secondary myopathic change than tibialis anterior. The following antibodies were used for muscle histochemistry: dystrophin: Dy10/12B2 (N term), Dy4/6 D3 (rod), and Dy8/6C5 (C term); associated glycoproteins: Ad1/20A6 (α-sarcoglycan), βSarc1/5B1 (β-sarcoglycan), 35DAG/21B5 (γ-sarcoglycan), δSarc3/12C1 (δ-sarcoglycan), and 43DAG/8D5 (β-dystroglycan); β-spectrin: RBC2/3D5 (to monitor membrane integrity on sections); laminins: commercial anti–laminin α5 (Chemicon MAB 1924), β1 (Chemicon MAB 1921) and γ1 chain (Chemicon MAB 1920), and Mer3/22B2 (equivalent to 300 kDa α2 chain fragment); caveolin 3, Emerin, and lamin A/C: commercial antibodies (Transduction Labs C38320 and Novocastra NCL-LAM-A/C, respectively); calpain 3: Calp3d/2C4 (exon 1) and Calp3c/12A2 (exon 8); dysferlin: NCL-hamlet (exon 53) and Ham3/17B2 (at exon 11-12 junction); and telethonin (G-11), neonatal myosin heavy chain (NCL-MHCn).
- Figure 2 Sequence validation, functional conservation, and Western blot data
(A) Sanger sequencing electropherograms demonstrating the segregation of the heterozygous HSPB1 c.387C>G variant with the disease phenotype in the 4 siblings. (B) Correspondence of the novel pathologic α-crystallin domain mutation site (in red) in human HSPB1 to human CRYAB and HSPB1 analogs in other species. Sites of known pathologic mutations are in blue. (C) Western blot of HSPB1 and CRYAB expression in control (F152, F153, and F011) and patient-derived fibroblasts before, and immediately after, heat shock by 1-hour incubation at 44°C.
Additional Files
Data Supplement
Files in this Data Supplement:
- Data Supplement - PDF
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg